Sophia G. Liva

Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor

Sophia G. Liva, Yu‐Chou Tseng, Anees M. Dauki et al. · EMBO Molecular Medicine · 2020 · 33 citations · Full text

A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

Katharine A. Collier, Hugo E. Valencia, Herbert B. Newton et al. · Cancer Chemotherapy and Pharmacology · 2021 · 25 citations · Full text

Neuro-oncology, Solid Malignancies, Medicine +6

Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans

Alyssa Marie M. Castillo, Trang T. Vu, Sophia G. Liva et al. · JCSM Rapid Communications · 2021 · 19 citations · Full text

Phase I study of AR-42 and decitabine in acute myeloid leukemia

Sophia G. Liva, Christopher C. Coss, Jiang Wang et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 18 citations · Full text

Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study

Peter C. Taylor, Georg Schett, T. Huizinga et al. · RMD Open · 2024 · 14 citations · Full text